These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 6295693)

  • 21. [Further observations on the use of Suloctidil (Sulocton) in the treatment of migraine].
    Prusiński A; Durko A; Głuszcz-Zielińska A; Szymańska R
    Wiad Lek; 1984 Dec; 37(23):1857-9. PubMed ID: 6099634
    [No Abstract]   [Full Text] [Related]  

  • 22. [Physical and exercise therapy of chronic obliterating arteriopathy of the lower limbs: clinical study].
    Galante M; Franchignoni F; Andina A; Grioni G
    Clin Ter; 1982 May; 101(4):357-62. PubMed ID: 7105641
    [No Abstract]   [Full Text] [Related]  

  • 23. [Study and evaluation of patients with obliterating arteriopathy of the lower limbs: use of isokinetics to analyze muscular strength and fatigue].
    Demonty B; Detaille V; Pasquier AY
    Ann Readapt Med Phys; 2004 Nov; 47(9):597-603. PubMed ID: 15539066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Suloctidil: long-term trial in the aged. Study of microcirculation, viscosity, red cell deformability, fibrinolysis and lipid fractions.
    Merchan R; Zurita IE; Martinez JF
    Arzneimittelforschung; 1985; 35(5):855-7. PubMed ID: 2992530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Intra-arterial infusion therapy in thrombo-obliterating diseases of the lower limbs].
    Kurbangaleev SM; Savel'ev IuS
    Vestn Khir Im I I Grek; 1974 Oct; 113(10):68-71. PubMed ID: 4432347
    [No Abstract]   [Full Text] [Related]  

  • 26. Therapeutic effects of nitrendipine (Bayotensin) in patients with arteriosclerosis obliterans of lower limbs.
    Grodzińska L; Basista M; Ohlrogge R
    Prog Clin Biol Res; 1989; 301():423-7. PubMed ID: 2678132
    [No Abstract]   [Full Text] [Related]  

  • 27. [Therapeutic use of a new vasoactive drug in cerebral vascular diseases in elderly patients].
    Petronio G; Scali G; Casa B; Nonis E
    Clin Ter; 1980 Aug; 94(4):427-44. PubMed ID: 6257445
    [No Abstract]   [Full Text] [Related]  

  • 28. [Continuous intra-arterial infusions in obliterating diseases of the lower limbs].
    Chudakov MI; Vorotyntsev SF
    Khirurgiia (Mosk); 1974 May; (5):87-90. PubMed ID: 4457694
    [No Abstract]   [Full Text] [Related]  

  • 29. Effects of suloctidil on platelet survival time following cardiac valve replacement.
    Col-de Beys C; Ferrant A; Moriau M
    Thromb Haemost; 1981 Aug; 46(2):550-3. PubMed ID: 6272442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A double-blind trial of suloctidil v. placebo in intermittent claudication.
    Jones NA; De Haas H; Zahavi J; Kakkar VV
    Br J Surg; 1982 Jan; 69(1):38-40. PubMed ID: 6274471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rationale for the use of drugs inhibiting platelet function in claudicating patients with atherosclerotic leg arteries.
    Verstraete M
    Agents Actions Suppl; 1984; 15():173-87. PubMed ID: 6091423
    [No Abstract]   [Full Text] [Related]  

  • 32. Intermittent claudication: Suloctidil v.s. placebo treatment.
    Holm J; Lindblad L; Scherstén T; Suurkula M
    Vasa; 1984; 13(2):175-8. PubMed ID: 6331019
    [No Abstract]   [Full Text] [Related]  

  • 33. [The use of regional artificial circulation in the treatment of obliterating thrombosis of the lower limbs].
    Dutkevich IG; Farshatov MN; Glebov IuI; Dekster BG
    Vestn Khir Im I I Grek; 1966 Jun; 96(6):122-6. PubMed ID: 6000568
    [No Abstract]   [Full Text] [Related]  

  • 34. [Indices of thrombocytic activity in patients with obliterating atherosclerosis of the arteries of the lower extremities].
    Iakunin GA; Kurguzov OP; Lavrova LA; Novikova AN
    Lab Delo; 1990; (3):77-8. PubMed ID: 1692921
    [No Abstract]   [Full Text] [Related]  

  • 35. [Clinical and instrumental evaluation of patients with chronic peripheral arterial occlusive disease after prolonged administration of suloctidil].
    Gregoratti L; Redaelli G; Limido P; Ghiringhelli L
    Clin Ter; 1982 Sep; 102(6):607-19. PubMed ID: 6291844
    [No Abstract]   [Full Text] [Related]  

  • 36. Controlled trial of suloctidil in intermittent claudication.
    Verhaeghe R; Van Hoof A; Beyens G
    J Cardiovasc Pharmacol; 1981; 3(2):279-86. PubMed ID: 6166799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical trial of suloctidil (sulocton) for the treatment of migraine (preliminary report)].
    Prusiński A
    Neurol Neurochir Pol; 1981; 15(3):309-11. PubMed ID: 6273762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erythrocyte deformability in patients with arteriosclerosis obliterans of lower limbs.
    Lukjan H; Rość D; Chyzy R; Szpak A
    Acta Med Pol; 1983; 24(1-4):55-63. PubMed ID: 6679687
    [No Abstract]   [Full Text] [Related]  

  • 39. [Blood coagulation in arteriosclerosis obliterans of the lower limbs].
    Chubar' SV
    Vrach Delo; 1978 Oct; (10):21-5. PubMed ID: 716352
    [No Abstract]   [Full Text] [Related]  

  • 40. [Suloctidil in the treatment of focal cerebral ischemia].
    Bartko D; Zúzi M; Brezná M; Trávniková M; Porubec V
    Cesk Neurol Neurochir; 1984 Mar; 47(2):103-8. PubMed ID: 6323038
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.